BCRX Annual Operating Expenses
$430.46 M
+$17.79 M+4.31%
31 December 2023
Summary:
As of January 22, 2025, BCRX annual total operating expenses is $430.46 million, with the most recent change of +$17.79 million (+4.31%) on December 31, 2023. During the last 3 years, it has risen by +$239.57 million (+125.50%). BCRX annual operating expenses is now at all-time high.BCRX Operating Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BCRX Quarterly Operating Expenses
$106.17 M
+$7.33 M+7.41%
30 September 2024
Summary:
As of January 22, 2025, BCRX quarterly total operating expenses is $106.17 million, with the most recent change of +$7.33 million (+7.41%) on September 30, 2024. Over the past year, it has dropped by -$28.27 million (-21.03%). BCRX quarterly operating expenses is now -21.03% below its all-time high of $134.43 million, reached on December 31, 2023.BCRX Quarterly Operating Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BCRX Operating Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +4.3% | -21.0% |
| 3 y3 years | +125.5% | +24.9% |
| 5 y5 years | +276.3% | +188.1% |
BCRX Operating Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +31.4% | -21.0% | +18.4% |
| 5 y | 5-year | at high | +198.5% | -21.0% | +184.9% |
| alltime | all time | at high | >+9999.0% | -21.0% | +2459.2% |
BioCryst Pharmaceuticals Operating Expenses History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $106.17 M(+7.4%) |
| June 2024 | - | $98.84 M(-6.6%) |
| Mar 2024 | - | $105.86 M(-21.3%) |
| Dec 2023 | $430.46 M(+4.3%) | $134.43 M(+37.8%) |
| Sept 2023 | - | $97.53 M(-4.6%) |
| June 2023 | - | $102.24 M(+6.2%) |
| Mar 2023 | - | $96.25 M(-22.0%) |
| Dec 2022 | $412.67 M(+26.0%) | $123.36 M(+37.6%) |
| Sept 2022 | - | $89.66 M(-10.3%) |
| June 2022 | - | $100.01 M(+0.4%) |
| Mar 2022 | - | $99.64 M(+0.7%) |
| Dec 2021 | $327.63 M(+71.6%) | $98.92 M(+16.4%) |
| Sept 2021 | - | $84.96 M(+7.3%) |
| June 2021 | - | $79.20 M(+22.8%) |
| Mar 2021 | - | $64.51 M(+14.5%) |
| Dec 2020 | $190.89 M(+32.4%) | $56.34 M(+18.8%) |
| Sept 2020 | - | $47.44 M(+14.6%) |
| June 2020 | - | $41.38 M(-9.5%) |
| Mar 2020 | - | $45.73 M(+22.7%) |
| Dec 2019 | $144.19 M(+26.0%) | $37.26 M(+1.1%) |
| Sept 2019 | - | $36.85 M(+1.4%) |
| June 2019 | - | $36.34 M(+7.7%) |
| Mar 2019 | - | $33.73 M(+20.8%) |
| Dec 2018 | $114.40 M(+41.4%) | $27.92 M(-6.7%) |
| Sept 2018 | - | $29.93 M(-1.9%) |
| June 2018 | - | $30.50 M(+17.1%) |
| Mar 2018 | - | $26.05 M(+20.5%) |
| Dec 2017 | $80.89 M(+11.9%) | $21.62 M(+3.7%) |
| Sept 2017 | - | $20.85 M(+12.1%) |
| June 2017 | - | $18.59 M(-6.2%) |
| Mar 2017 | - | $19.83 M(+34.7%) |
| Dec 2016 | $72.26 M(-15.8%) | $14.72 M(-12.7%) |
| Sept 2016 | - | $16.86 M(-0.2%) |
| June 2016 | - | $16.89 M(-29.0%) |
| Mar 2016 | - | $23.79 M(+9.3%) |
| Dec 2015 | $85.81 M(+44.8%) | $21.77 M(-4.5%) |
| Sept 2015 | - | $22.80 M(+13.7%) |
| June 2015 | - | $20.06 M(-5.3%) |
| Mar 2015 | - | $21.18 M(+3.0%) |
| Dec 2014 | $59.26 M(+23.6%) | $20.56 M(+38.5%) |
| Sept 2014 | - | $14.85 M(+13.5%) |
| June 2014 | - | $13.08 M(+21.4%) |
| Mar 2014 | - | $10.77 M(-36.2%) |
| Dec 2013 | $47.95 M(-17.7%) | $16.88 M(+81.3%) |
| Sept 2013 | - | $9.31 M(-28.1%) |
| June 2013 | - | $12.96 M(+47.4%) |
| Mar 2013 | - | $8.79 M(-32.5%) |
| Dec 2012 | $58.29 M(-15.8%) | $13.02 M(-4.7%) |
| Sept 2012 | - | $13.66 M(-5.0%) |
| June 2012 | - | $14.39 M(-16.5%) |
| Mar 2012 | - | $17.22 M(+5.9%) |
| Dec 2011 | $69.23 M(-27.6%) | $16.27 M(-9.9%) |
| Sept 2011 | - | $18.05 M(+0.4%) |
| June 2011 | - | $17.98 M(+6.2%) |
| Mar 2011 | - | $16.93 M(-34.8%) |
| Dec 2010 | $95.62 M(+14.1%) | $25.97 M(+13.0%) |
| Sept 2010 | - | $22.99 M(+28.1%) |
| June 2010 | - | $17.95 M(-37.5%) |
| Mar 2010 | - | $28.71 M(-18.6%) |
| Dec 2009 | $83.78 M | $35.27 M(+66.0%) |
| Sept 2009 | - | $21.25 M(+57.1%) |
| Date | Annual | Quarterly |
|---|---|---|
| June 2009 | - | $13.53 M(-1.6%) |
| Mar 2009 | - | $13.75 M(-43.7%) |
| Dec 2008 | $83.73 M(-19.1%) | $24.44 M(+32.3%) |
| Sept 2008 | - | $18.47 M(+15.1%) |
| June 2008 | - | $16.04 M(-35.3%) |
| Mar 2008 | - | $24.78 M(-21.6%) |
| Dec 2007 | $103.52 M(+94.6%) | $31.60 M(-2.2%) |
| Sept 2007 | - | $32.33 M(+53.7%) |
| June 2007 | - | $21.03 M(+108.2%) |
| Mar 2007 | - | $10.10 M(-21.3%) |
| Dec 2006 | $53.19 M(+94.6%) | $12.83 M(-29.7%) |
| Sept 2006 | - | $18.25 M(+45.1%) |
| June 2006 | - | $12.57 M(+31.8%) |
| Mar 2006 | - | $9.54 M(+27.0%) |
| Dec 2005 | $27.33 M(+23.7%) | $7.51 M(-5.7%) |
| Sept 2005 | - | $7.96 M(+32.9%) |
| June 2005 | - | $5.99 M(+2.0%) |
| Mar 2005 | - | $5.87 M(+4.7%) |
| Dec 2004 | $22.09 M(+54.1%) | $5.61 M(+0.7%) |
| Sept 2004 | - | $5.57 M(+5.5%) |
| June 2004 | - | $5.27 M(-6.5%) |
| Mar 2004 | - | $5.64 M(+38.1%) |
| Dec 2003 | $14.33 M(-23.4%) | $4.09 M(+12.6%) |
| Sept 2003 | - | $3.63 M(+3.2%) |
| June 2003 | - | $3.52 M(+13.6%) |
| Mar 2003 | - | $3.10 M(-10.8%) |
| Dec 2002 | $18.70 M(+15.9%) | $3.47 M(-9.3%) |
| Sept 2002 | - | $3.83 M(-27.1%) |
| June 2002 | - | $5.25 M(-14.7%) |
| Mar 2002 | - | $6.16 M(+2.2%) |
| Dec 2001 | $16.14 M(+22.8%) | $6.03 M(+71.2%) |
| Sept 2001 | - | $3.52 M(-1.7%) |
| June 2001 | - | $3.58 M(+9.5%) |
| Mar 2001 | - | $3.27 M(-15.3%) |
| Dec 2000 | $13.15 M(+18.4%) | $3.86 M(+40.5%) |
| Sept 2000 | - | $2.75 M(-24.1%) |
| June 2000 | - | $3.62 M(+15.6%) |
| Mar 2000 | - | $3.13 M(+25.2%) |
| Dec 1999 | $11.10 M(-14.0%) | $2.50 M(-7.4%) |
| Sept 1999 | - | $2.70 M(-6.9%) |
| June 1999 | - | $2.90 M(-6.5%) |
| Mar 1999 | - | $3.10 M(+34.8%) |
| Dec 1998 | $12.90 M(-7.2%) | $2.30 M(-37.8%) |
| Sept 1998 | - | $3.70 M(+2.8%) |
| June 1998 | - | $3.60 M(+5.9%) |
| Mar 1998 | - | $3.40 M(-2.9%) |
| Dec 1997 | $13.90 M(+28.7%) | $3.50 M(+12.9%) |
| Sept 1997 | - | $3.10 M(-16.2%) |
| June 1997 | - | $3.70 M(+362.5%) |
| Mar 1997 | - | $800.00 K(-70.4%) |
| Dec 1996 | $10.80 M(+285.7%) | $2.70 M(-3.6%) |
| Sept 1996 | - | $2.80 M(-12.5%) |
| June 1996 | - | $3.20 M(+52.4%) |
| Mar 1996 | - | $2.10 M(-146.7%) |
| Dec 1995 | $2.80 M(+12.0%) | -$4.50 M(-295.7%) |
| Sept 1995 | - | $2.30 M(+21.1%) |
| June 1995 | - | $1.90 M(-42.4%) |
| Mar 1995 | - | $3.30 M(+560.0%) |
| Dec 1994 | $2.50 M | $500.00 K(-16.7%) |
| Sept 1994 | - | $600.00 K(-25.0%) |
| June 1994 | - | $800.00 K(+14.3%) |
| Mar 1994 | - | $700.00 K |
FAQ
- What is BioCryst Pharmaceuticals annual total operating expenses?
- What is the all time high annual operating expenses for BioCryst Pharmaceuticals?
- What is BioCryst Pharmaceuticals annual operating expenses year-on-year change?
- What is BioCryst Pharmaceuticals quarterly total operating expenses?
- What is the all time high quarterly operating expenses for BioCryst Pharmaceuticals?
- What is BioCryst Pharmaceuticals quarterly operating expenses year-on-year change?
What is BioCryst Pharmaceuticals annual total operating expenses?
The current annual operating expenses of BCRX is $430.46 M
What is the all time high annual operating expenses for BioCryst Pharmaceuticals?
BioCryst Pharmaceuticals all-time high annual total operating expenses is $430.46 M
What is BioCryst Pharmaceuticals annual operating expenses year-on-year change?
Over the past year, BCRX annual total operating expenses has changed by +$17.79 M (+4.31%)
What is BioCryst Pharmaceuticals quarterly total operating expenses?
The current quarterly operating expenses of BCRX is $106.17 M
What is the all time high quarterly operating expenses for BioCryst Pharmaceuticals?
BioCryst Pharmaceuticals all-time high quarterly total operating expenses is $134.43 M
What is BioCryst Pharmaceuticals quarterly operating expenses year-on-year change?
Over the past year, BCRX quarterly total operating expenses has changed by -$28.27 M (-21.03%)